Clin2
NCT05208710Possibly a fitRecruiting

Study new HPV vaccine in healthy adults

HPV

Treatments studied

Part of Infections clinical trials.

This early study tests a new HPV (human papillomavirus) vaccine to see if it can safely trigger an immune response in healthy adults. It’s for people who have not had an HPV vaccine before and can follow study vaccination and pregnancy-prevention rules.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
45 people
Ages
18 years to 45 years
Study type
Interventional

Who can take part

  • You can sign consent and follow the study rules and visit schedule
  • You are age 18 to 45 when you sign up
  • You must use highly effective birth control during the study and for 4 weeks after each shot, unless you cannot become pregnant or will be abstinent
  • You cannot get any commercially available HPV vaccine during the study
  • You should not have had an HPV vaccine before, and you shouldn’t have had a vaccine in the last 28 days
  • No certain medical issues that could make vaccination unsafe or affect your immune response (including some blood test and allergy results)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06220747Recruiting
HPV vaccine study for women ages 12 to 45

This study tests how well the HPV vaccine works in women and teens. It's for those who are willing to get an HPV test and haven't already had all 3 doses of the vaccine.

Bangkok, Select...
NCT07303751Not yet recruiting· Phase 2
HPV vaccine trial to reduce virus spread in women

This study tests if a single dose of the HPV vaccine (Gardasil 9) can lower the amount of HPV virus in women who already have the virus, potentially reducing how easily it spreads. It will help us learn if vaccination can protect partners and communities.

Freetown
NCT07431502Not yet recruiting· Phase 3
HPV vaccine to prevent precancerous lesions from returning

This trial tests whether an HPV vaccine (the nonavalent type) can help prevent the same precancerous lesions from coming back after treatment. It is for people who currently have a high-grade HPV-related lesion but have not yet been treated for it.

NCT05027776Recruiting· Phase 3
HPV vaccine study for healthy girls and young women

This trial studies whether a quadrivalent HPV vaccine is safe and helps the body build protection (immunity) against HPV. It enrolls healthy Chinese females who are not already treated for HPV-related infection.

Mianyang, Sichuan
NCT06756269Recruiting· Phase 2
HPV vaccine study for people aged 9 to 45

This trial tests a new 15-valent HPV vaccine to see if it is safe and creates a strong immune response. If you are between 9 and 45 years old and have not had an HPV vaccine before, you may be able to join.

Nanning, Guangxi
NCT05262010Recruiting· Phase 3
HPV vaccine study for Chinese women, ages 9–45

This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.

Hechi, Guangxi

Hear when a new HPV trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.